We are live on ! Find out more
SBBP

Strongbridge Biopharma plc.
SBBP

Delisted

SBBP was delisted on the 5th of October, 2021.

42 hedge funds and large institutions have $119M invested in Strongbridge Biopharma plc. in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

76% more call options, than puts

Call options by funds: $51K | Put options by funds: $29K

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

14% less funds holding

Funds holding: 4942 (-7)

20% less capital invested

Capital invested by funds: $149M → $119M (-$29.9M)

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
42
Holders Change
-7
Holders Change %
-14.29%
% of All Funds
0.94%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
9
Increased
14
Reduced
16
Closed
16
Calls
$51K
Puts
$29K
Net Calls
+$22K
Net Calls Change
-$6K
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Caxton Corporation
New Jersey
$29.6M +$1.51M +309,276 +5%
NMC
2
NEA Management Company
Maryland
$18.6M
AC
3
Armistice Capital
New York
$12.9M +$1.11M +228,000 +9%
BC
4
Broadfin Capital
New York
$12.6M +$1.26M +258,626 +10%
PWAM
5
Park West Asset Management
California
$6.83M -$244K -50,000 -3%
OM
6
Opaleye Management
Massachusetts
$6.23M -$1.66M -340,000 -20%
Hudson Bay Capital Management
7
Hudson Bay Capital Management
Connecticut
$4.48M +$1.59M +324,900 +48%
PM
8
Prosight Management
Texas
$4.2M +$2.51M +514,054 +121%
SFM
9
Sphera Funds Management
Israel
$4.17M -$1.21M -247,410 -21%
6CM
10
683 Capital Management
New York
$3.8M +$2.68M +549,000 +183%
BlackRock
11
BlackRock
New York
$2.48M -$194K -39,708 -7%
HCS
12
Harvest Capital Strategies
California
$2.44M -$1.74M -356,348 -40%
EIM
13
Essex Investment Management
Massachusetts
$2.21M +$294K +60,214 +14%
2L
14
22NW LP
Washington
$1.81M +$1.97M +404,410 New
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$1.59M +$821K +168,243 +90%
TAF
16
Tredje AP-fonden
Sweden
$851K -$135K -27,602 -13%
Millennium Management
17
Millennium Management
New York
$730K -$2.32M -474,721 -74%
Deutsche Bank
18
Deutsche Bank
Germany
$518K -$43.5K -8,910 -7%
State Street
19
State Street
Massachusetts
$399K +$21.7K +4,454 +5%
Wells Fargo
20
Wells Fargo
California
$300K +$119K +24,318 +57%
PCM
21
Prelude Capital Management
New York
$256K +$73.5K +15,047 +36%
BFM
22
Boothbay Fund Management
New York
$233K +$254K +52,000 New
PP
23
PDT Partners
New York
$183K
Two Sigma Investments
24
Two Sigma Investments
New York
$182K -$863K -176,791 -81%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$167K

SBBP Hedge Fund Activity: Q4 2018 in Review

42 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Strongbridge Biopharma plc. (SBBP) for Q4 2018, worth a combined $119M — down 20% from $149M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of SBBP and 9 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 14 added.

The largest buyer was 683 Capital Management, adding an estimated $2.68M. The largest seller was Lyon Street Capital, exiting entirely with an estimated $13.9M sold.

  • 42 institutional investors held Strongbridge Biopharma plc. (SBBP) as of Q4 2018, down from 49 in Q3 2018.
  • Funds reported $119M of Strongbridge Biopharma plc. stock for Q4 2018, down 20% quarter-over-quarter.
  • 9 funds opened new Strongbridge Biopharma plc. positions in Q4 2018 and 16 closed out, a net change of -7 holders.
  • The largest Strongbridge Biopharma plc. buyer in Q4 2018 was 683 Capital Management, an estimated $2.68M added.
  • The largest Strongbridge Biopharma plc. seller in Q4 2018 was Lyon Street Capital, an estimated $13.9M sold.

Based on aggregated 13F filings for Q4 2018.